Short answer
NEOGENOMICS INC (NEO) filed its Q3 2025 10-Q quarterly report on Oct 28, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $188M (up 11.9% year over year) with net income of −$27M.
Q3 2025 key financials · XBRL
- Revenue
- $188M
- +11.9% YoY · +3.6% QoQ
- Net income
- −$27M
- −53.3% YoY · +39.8% QoQ
- Operating margin
- -14.4%
- Gross margin
- 42.8%
Source: XBRL data from the NEOGENOMICS INC (NEO) Q3 2025 10-Q on SEC EDGAR. USD.
NEOGENOMICS INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new risk factors added this quarter; risk profile consistent with 2024 Form 10-K
- Most materially updated risk: no specific changes disclosed in current 10-Q
- Regulatory risk: ongoing compliance with evolving FDA and CMS regulations critical for lab services reimbursement
- Operational risk: dependency on timely integration of acquisitions affecting near-term revenue growth
- Financial risk: liquidity management pivotal given $100M debt maturing in next 18 months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other NEOGENOMICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.